Summary

The oral direct factor Xa inhibitor betrixaban, at doses of 40 mg, 60 mg, and 80 mg once daily, is safe and well tolerated compared with dose-adjusted warfarin in patients with nonvalvular atrial fibrillation (AF) or atrial flutter. This article presents results from the Phase II, randomized, multicenter EXPLORE-Xa Trial [NCT00742859].